Antigen: human IP receptor N-terminal amino acids 1-16 conjugated to KLH (MADSCRNLTYVRGSVG) · Host: rabbit · Application(s): WB; other applications not tested · Prostaglandin I₂ (PGI₂) is a potent vasorelaxant and inhibitor of human platelet aggregation.¹ The PGI₂ receptor (IP receptor) also participates in signal transduction of the pain response, cardioprotection, and inflammation.^2,3,4,5,6 Cloning of the murine and human IP receptors revealed a significant amino-terminal truncation of the human IP receptor compared to the murine receptor.^7,8 Cayman Chemical’s IP receptor antibody detects a 67 kDa band on immunoblot. The predicted migration of the deglycosylated protein is 40 kDa and bands at either 67 or 40 kDa may be detected depending on the degree of post-translational modification of the sample.⁹

1 Aristoff, P.A., Johnson, P.D., and Harrison, A.W. Synthesis of 9-substituted carbacyclin analogues. J Org Chem 48 5341-5348 (1983).

2 Southall, M.D., and Vasko, M.R. Prostaglandin receptor subtypes, EP3C and EP₄, mediate the prostaglandin E₂-induced cAMP production and sensitization of sensory neurons. J Biol Chem 276(19) 16083-16091 (2001).

3 Murata, T., Ushikubi, F., Matsuoka, T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 678-682 (1997).

4 Cheng, Y., Austin, S.C., Rocca, B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A₂. Science 296 539-541 (2002).

5 Cui, Y., Kataoka, Y., Satoh, T., et al. Protective effect of prostaglandin I₂ analogs on ischemic delayed neuronal damage in gerbils. Biochem Biophys Res Commun 265 301-304 (1999).

6 McLaughlin, V.V., Genthner, D.E., Panella, M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 273-277 (1998).

7 Nakagawa, O., Tanaka, I., Usui, T., et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90 1643-1647 (1994).

8 Namba, T., Oida, H., Sugimoto, Y., et al. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 269 9986-9992 (1994).

9 Smyth, E.M., Nestor, P.V., and Fitzgerald, G.A. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 271(52) 33698-33704 (1996).

Aristoff, P.A., Johnson, P.D., and Harrison, A.W. Synthesis of 9-substituted carbacyclin analogues. J Org Chem 48 5341-5348 (1983).

Nakagawa, O., Tanaka, I., Usui, T., et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90 1643-1647 (1994).

Namba, T., Oida, H., Sugimoto, Y., et al. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 269 9986-9992 (1994).

Smyth, E.M., Nestor, P.V., and Fitzgerald, G.A. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 271(52) 33698-33704 (1996).

McLaughlin, V.V., Genthner, D.E., Panella, M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 273-277 (1998).

Southall, M.D., and Vasko, M.R. Prostaglandin receptor subtypes, EP3C and EP₄, mediate the prostaglandin E₂-induced cAMP production and sensitization of sensory neurons. J Biol Chem 276(19) 16083-16091 (2001).

Murata, T., Ushikubi, F., Matsuoka, T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 678-682 (1997).

Cui, Y., Kataoka, Y., Satoh, T., et al. Protective effect of prostaglandin I₂ analogs on ischemic delayed neuronal damage in gerbils. Biochem Biophys Res Commun 265 301-304 (1999).

Cheng, Y., Austin, S.C., Rocca, B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A₂. Science 296 539-541 (2002).

Show all 9 Hide all but first 3